Cellply Revenue and Competitors
Estimated Revenue & Valuation
- Cellply's estimated annual revenue is currently $4M per year.
- Cellply's estimated revenue per employee is $122,182
Employee Data
- Cellply has 33 Employees.
- Cellply grew their employee count by 0% last year.
Cellply's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Managing Director | Reveal Email/Phone |
2 | Head Biology | Reveal Email/Phone |
3 | Business Development Manager EU | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
5 | Software Developer | Reveal Email/Phone |
6 | Hardware Engineer | Reveal Email/Phone |
Cellply Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.6M | 90 | -36% | $14.1M | N/A |
#2 | $83.2M | 468 | -3% | $251M | N/A |
#3 | $14M | 103 | 11% | N/A | N/A |
#4 | $14.6M | 0 | N/A | $12.5M | N/A |
#5 | $30.3M | 197 | -6% | N/A | N/A |
#6 | $0.1M | 11 | 83% | $2.6M | N/A |
#7 | $45.1M | 293 | 2% | N/A | N/A |
#8 | $4.8M | 39 | -2% | N/A | N/A |
#9 | $399.3M | 2037 | 40% | N/A | N/A |
#10 | $44M | 276 | 4% | N/A | N/A |
What Is Cellply?
Cellply is a life-science company that develops in-vitro diagnostic platforms supporting personalized cancer treatment. Through the use of proprietary microtechnologies, diagnostic tests defining cell response to drug treatments are made available at the bedside. Results of the fully automated analysis guide anatomo-pathologists and oncologists in choosing the best drug therapy after cells from each patient have been exposed to several candidate drugs. Cellply is an innovative start-up company based in Bologna, Italy. The company received a first round of VC financing in 2014.
keywords:N/AN/A
Total Funding
33
Number of Employees
$4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.3M | 47 | -4% | N/A |
#2 | $8.3M | 47 | 9% | N/A |
#3 | N/A | 48 | 30% | $24M |
#4 | $7.7M | 59 | N/A | N/A |
#5 | $7.7M | 62 | 9% | N/A |